NEW YORK (GenomeWeb News) - Takara Bio has licensed to InVivoScribe Technologies its patent for detecting the mutations of FMS-like tyrosine kinase 3 genes, Takara Bio said today.
Under the agreement, InVivoScribe will receive an exclusive license to use the patent worldwide, except in Japan. The company will be allowed to develop, manufacture, and sell a reagent for detecting FLT3 gene mutations. It can also sublicense the patent to others.
InVivoScribe Technologies will make an upfront payment and royalties on sales and sublicenses to Takara Bio.